A medical device company has strong team delivery metrics, but its portfolio dashboard shows delayed benefits and too many simultaneous initiatives. The current decision centers on WSJF, and leaders have competing proposals from Finance, Product Management, and the ARTs. Which option is the most defensible portfolio-level decision?
